CMA reaccuses Pfizer and Flynn of excessive pricing
The UK’s Competition and Markets Authority has accused Pfizer and Flynn Pharma of charging unfairly high prices for an anti-epilepsy medication, 17 months after an appellate court ordered the agency to redo parts of its initial probe into the drugmakers.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10